Immuron has just recorded its highest ever quarterly sales of Travelan, bringing in $1,550,240 of sales through the first quarter of the 2024 Financial Year from its over-the-counter immune supplement used to treat traveler’s diarrhea.
It marked a $1,508,933 increase over the first quarter of last year and was 130 per cent higher than the pre-pandemic mark achieved in 2020.
And Immuron expect more to come from replenishment demand as retail pharmacies restock and short-term resident returns begin to approach pre-pandemic levels.
Inventory had also been shipped to Amazon for its launch on US shores, where the company trades on the NASDAQ, has been progressing with sales ahead of budget, and anticipate strong sales from the peak travel period in warmer weather.
About Travelan
Traveler’s diarrhea is the leading cause of disability among international passengers to developing countries, and around a fifth of people experience severe symptoms requiring bed rest, with a tenth of cases persisting for over a week.
It can seriously threaten health and wellbeing and is particularly dangerous the young, the elderly, and anyone with a weakened immune system.
It was a largely unaddressed issue which led to the development of Travelan, using an active bovine colostrum ingredient enriched with unique anti-E.coli antibodies which sets the product apart from other supplements -and being antimicrobial, it causes no antibiotic resistance.
Next trials
Clinical trials have already demonstrated that the product significantly decreases the risks of traveler’s diarrhea and lowers the symptoms of more minor disorders.
The trials showed protection up to 90 cent against E.coli and significantly less discomfort and diarrhea in those affected that did not take the supplement, while studies by the US Defense force demonstrated it was cross-reactive to other pathogenic bacteria.
While already approved and available to purchase over the counter in Australia, the US, and Canada, Immuron is now conducting a Phase 2 clinical study over Travelan, and evidence has so far been promising for the aims to add data from over-the-counter sales to prove its efficacy for approval as a drug by the Food and Drug Administration.
